Phibro Animal Health Is Maintained at Underweight by Barclays
Barclays Maintains Phibro Animal Health(PAHC.US) With Sell Rating, Raises Target Price to $20
Barclays Sticks to Their Sell Rating for Phibro Animal Health (PAHC)
Barclays Maintains Phibro Animal Health(PAHC.US) With Sell Rating, Maintains Target Price $13
Barclays Remains a Sell on Phibro Animal Health (PAHC)
Phibro Animal Health Analyst Ratings
JP Morgan Initiates Coverage On Phibro Animal Health With Neutral Rating, Announces Price Target of $22
J.P. Morgan Initiates Phibro Animal Health(PAHC.US) With Hold Rating, Announces Target Price $22
Phibro Animal Health Analyst Ratings
B of A Securities Maintains Underperform on Phibro Animal Health, Raises Price Target to $15
BofA Securities Maintains Phibro Animal Health(PAHC.US) With Sell Rating, Raises Target Price to $15
Barclays Maintains Phibro Animal Health(PAHC.US) With Sell Rating, Maintains Target Price $13
Phibro Animal Health (PAHC) Receives a Sell From Barclays
BofA Securities Maintains Phibro Animal Health(PAHC.US) With Sell Rating, Raises Target Price to $13
Phibro Animal Health Sell Rating: Concerns Over Operating Leverage and Profitability Despite Revenue Growth
Analysts Offer Insights on Healthcare Companies: Phibro Animal Health (PAHC) and Veeva Systems (VEEV)
Barclays: Maintaining the Phibro Animal Health (PAHC.US) rating, adjusted from reduced holdings to reduced holdings rating, and adjusted the target price from $10.00 to $13.00.
Phibro Animal Health Analyst Ratings
Barclays Maintains Underweight on Phibro Animal Health, Raises Price Target to $13
Analysts' Opinions Are Mixed on These Healthcare Stocks: Cytokinetics (CYTK), Phibro Animal Health (PAHC) and Amphastar Pharmaceuticals (AMPH)